Tags

Type your tag names separated by a space and hit enter

A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world.
Int J Chron Obstruct Pulmon Dis. 2015; 10:2127-36.IJ

Abstract

BACKGROUND

Roflumilast is approved in the United States to reduce the risk of COPD exacerbations in patients with severe COPD. Exacerbation rates, health care resource utilization (HCRU), and costs were compared between roflumilast patients and those receiving other COPD maintenance drugs.

METHODS

LifeLink™ Health Plan Claims Database was used to identify patients diagnosed with COPD who initiated roflumilast (roflumilast group) or ≥3 other COPD maintenance drugs (non-roflumilast group) from May 1, 2011 to December 31, 2012. Patients must have been enrolled for 12 months before (baseline) and 3 months after (postindex) the initiation date, ≥40 years old, not systemic corticosteroid dependent, and without asthma diagnosis at baseline. Difference-in-difference models compared change from baseline in exacerbations, HCRU (office, emergency visits, and hospitalizations), and total costs between groups, adjusting for baseline differences.

RESULTS

A total of 14,211 patients (roflumilast, n=710; non-roflumilast, n=13,501) were included. During follow-up, the rate of overall exacerbations per patient per month decreased by 11.1% in the roflumilast group and increased by 15.9% in the non-roflumilast group (P<0.001). After controlling for baseline differences, roflumilast-treated patients experienced a greater reduction in exacerbations (0.0160 fewer exacerbations per month, P=0.01), numerically greater reductions in hospital admissions (0.003 fewer per month, P=0.57), office visits (0.46 fewer per month, P=0.26), and total costs from baseline compared with non-roflumilast patients ($116 less per month, P=0.62).

CONCLUSION

In a real-world setting, patients initiating roflumilast experienced reductions in exacerbations versus patients treated with other COPD medications.

Authors+Show Affiliations

Health Economics and Modeling, Outcomes Research, Pharmerit International, Bethesda, MD, USA.Health Economics and Outcomes Research, Forest Laboratories, LLC, an affiliate of Actavis, Inc., Jersey City, NJ, USA.Health Economics and Modeling, Outcomes Research, Pharmerit International, Bethesda, MD, USA.Health Economics and Outcomes Research, Forest Laboratories, LLC, an affiliate of Actavis, Inc., Jersey City, NJ, USA.Health Economics and Modeling, Outcomes Research, Pharmerit International, Bethesda, MD, USA.Pulmonary Critical Care, Washington Hospital Center and Georgetown University, Washington, DC, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26504378

Citation

Wan, Yin, et al. "A Longitudinal, Retrospective Cohort Study On the Impact of Roflumilast On Exacerbations and Economic Burden Among Chronic Obstructive Pulmonary Disease Patients in the Real World." International Journal of Chronic Obstructive Pulmonary Disease, vol. 10, 2015, pp. 2127-36.
Wan Y, Sun SX, Corman S, et al. A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world. Int J Chron Obstruct Pulmon Dis. 2015;10:2127-36.
Wan, Y., Sun, S. X., Corman, S., Huang, X., Gao, X., & Shorr, A. F. (2015). A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world. International Journal of Chronic Obstructive Pulmonary Disease, 10, 2127-36. https://doi.org/10.2147/COPD.S80106
Wan Y, et al. A Longitudinal, Retrospective Cohort Study On the Impact of Roflumilast On Exacerbations and Economic Burden Among Chronic Obstructive Pulmonary Disease Patients in the Real World. Int J Chron Obstruct Pulmon Dis. 2015;10:2127-36. PubMed PMID: 26504378.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world. AU - Wan,Yin, AU - Sun,Shawn X, AU - Corman,Shelby, AU - Huang,Xingyue, AU - Gao,Xin, AU - Shorr,Andrew F, Y1 - 2015/10/07/ PY - 2015/10/28/entrez PY - 2015/10/28/pubmed PY - 2016/7/12/medline KW - COPD KW - PDE-4 inhibitor KW - health care resource utilization KW - outcomes SP - 2127 EP - 36 JF - International journal of chronic obstructive pulmonary disease JO - Int J Chron Obstruct Pulmon Dis VL - 10 N2 - BACKGROUND: Roflumilast is approved in the United States to reduce the risk of COPD exacerbations in patients with severe COPD. Exacerbation rates, health care resource utilization (HCRU), and costs were compared between roflumilast patients and those receiving other COPD maintenance drugs. METHODS: LifeLink™ Health Plan Claims Database was used to identify patients diagnosed with COPD who initiated roflumilast (roflumilast group) or ≥3 other COPD maintenance drugs (non-roflumilast group) from May 1, 2011 to December 31, 2012. Patients must have been enrolled for 12 months before (baseline) and 3 months after (postindex) the initiation date, ≥40 years old, not systemic corticosteroid dependent, and without asthma diagnosis at baseline. Difference-in-difference models compared change from baseline in exacerbations, HCRU (office, emergency visits, and hospitalizations), and total costs between groups, adjusting for baseline differences. RESULTS: A total of 14,211 patients (roflumilast, n=710; non-roflumilast, n=13,501) were included. During follow-up, the rate of overall exacerbations per patient per month decreased by 11.1% in the roflumilast group and increased by 15.9% in the non-roflumilast group (P<0.001). After controlling for baseline differences, roflumilast-treated patients experienced a greater reduction in exacerbations (0.0160 fewer exacerbations per month, P=0.01), numerically greater reductions in hospital admissions (0.003 fewer per month, P=0.57), office visits (0.46 fewer per month, P=0.26), and total costs from baseline compared with non-roflumilast patients ($116 less per month, P=0.62). CONCLUSION: In a real-world setting, patients initiating roflumilast experienced reductions in exacerbations versus patients treated with other COPD medications. SN - 1178-2005 UR - https://www.unboundmedicine.com/medline/citation/26504378/A_longitudinal_retrospective_cohort_study_on_the_impact_of_roflumilast_on_exacerbations_and_economic_burden_among_chronic_obstructive_pulmonary_disease_patients_in_the_real_world_ L2 - https://dx.doi.org/10.2147/COPD.S80106 DB - PRIME DP - Unbound Medicine ER -